Unicycive Therapeutics Faces Class Action Lawsuit: Key Insights

Author: Evelyn Baker Updated: 09-29-2025 05:12 PM

Overview of Unicycive's Legal Situation

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is currently facing a class action lawsuit that has raised concerns among investors. The law firm Bragar Eagel & Squire, P.C., known for its focus on protecting shareholders' rights, has stepped forward to encourage those affected by the company's alleged misrepresentation of its manufacturing compliance capabilities for a new drug application.

Details of the Allegations

The lawsuit stems from claims that Unicycive misled investors about its New Drug Application (NDA) for oxylanthanum carbonate (OLC), intended for treating hyperphosphatemia in chronic kidney disease patients undergoing dialysis. The complaint alleges that the company's assurances regarding its readiness to meet regulatory compliance were significantly exaggerated.

Impact of the FDA Findings

On June 10, 2025, it was revealed that the FDA had detected significant deficiencies in the current good manufacturing practices (cGMP) at one of Unicycive's contracted manufacturing vendors. This information fundamentally altered the perception of the company’s operational readiness, resulting in a sharp decline in stock value—over 40% at the time.

Continued Stock Decline

The series of unfortunate announcements continued when, on June 30, 2025, Unicycive disclosed that the FDA had sent a Complete Response Letter regarding the OLC NDA, referencing ongoing compliance issues at the same manufacturing partner. This event further impacted the stock price, which plummeted nearly 30% to close at $4.77 per share on that date.

Next Steps for Investors

Investors who purchased Unicycive shares between March 29, 2024, and June 27, 2025, and have experienced a financial loss, are advised to consult with the firm Bragar Eagel & Squire, P.C. The deadline for investors to apply to be appointed as lead plaintiff in the class action is approaching, with a date set for October 14, 2025.

How to Participate

Anyone who may have suffered due to the discrepancy in Unicycive’s reported manufacturing capabilities is encouraged to reach out for guidance on their legal options. The firm emphasizes that there is no financial obligation to discuss potential claims.

Bragar Eagel & Squire, P.C.: Advocates for Shareholder Rights

The law firm, Bragar Eagel & Squire, P.C., boasts a strong track record of standing up for individual and institutional investors. They handle various complex litigation cases across many jurisdictions and possess substantial expertise in securities law. For those interested in learning more about their approach or the specifics of the case, detailed information can be obtained directly from their website.

Frequently Asked Questions

What is the current situation for Unicycive Therapeutics?

Unicycive is facing a class action lawsuit for allegedly misleading investors about its readiness to meet FDA manufacturing requirements.

Who should consider joining the class action?

Investors who acquired stock in Unicycive between March 29, 2024, and June 27, 2025, and suffered losses should consider joining the class action.

What led to the significant stock price drop?

Announcements regarding compliance issues revealed by the FDA significantly impacted investor confidence, leading to substantial stock price declines.

What should I do if I'm a Unicycive investor?

If you are a Unicycive investor, it is advisable to contact Bragar Eagel & Squire, P.C. to understand your rights and options.

What is the deadline for joining the lawsuit?

The deadline to apply as a lead plaintiff in the class action lawsuit is set for October 14, 2025.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.